Dyax expands Sigma-Tau partnership, potential payments
Dyax Corp. has expanded a partnership with the Sigma-Tau SpA subsidiary Defiante Farmaceutica S.A. of Portugal, bringing the Cambridge biotech’s under-the-skin treatment for hereditary angioedema, called DX-88 and marketed as Kalbitor, to more countries. The deal is expected to bring Dyax $7 million in upfront payments, with the potential to receive up to $10 million more in regulatory and milestone pay.
Under a previous deal between the two companies, Kalbitor was being developed and commercialized in Europe, North Africa, Middle East and Russia. The new deal expands that coverage to include development and commercialization rights in Latin America, excluding Mexico and the Caribbean, Taiwan, Singapore and South Korea.